BR112014028632A2 - composto , composição farmacêutica , e , métodos de prepara um composto e de tratamento de uma infecção viral - Google Patents

composto , composição farmacêutica , e , métodos de prepara um composto e de tratamento de uma infecção viral

Info

Publication number
BR112014028632A2
BR112014028632A2 BR112014028632A BR112014028632A BR112014028632A2 BR 112014028632 A2 BR112014028632 A2 BR 112014028632A2 BR 112014028632 A BR112014028632 A BR 112014028632A BR 112014028632 A BR112014028632 A BR 112014028632A BR 112014028632 A2 BR112014028632 A2 BR 112014028632A2
Authority
BR
Brazil
Prior art keywords
compound
treating
preparing
methods
pharmaceutical composition
Prior art date
Application number
BR112014028632A
Other languages
English (en)
Other versions
BR112014028632B1 (pt
BR112014028632A8 (pt
Inventor
Bergman Jan
Homman Mohammed
Kingi Ngarita
Berg Robert
Original Assignee
Vironova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48444409&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014028632(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vironova Ab filed Critical Vironova Ab
Publication of BR112014028632A2 publication Critical patent/BR112014028632A2/pt
Publication of BR112014028632A8 publication Critical patent/BR112014028632A8/pt
Publication of BR112014028632B1 publication Critical patent/BR112014028632B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014028632A 2012-05-18 2013-05-17 composto, composição farmacêutica, e, método para preparar um composto BR112014028632B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648700P 2012-05-18 2012-05-18
US201261659516P 2012-06-14 2012-06-14
US201261666286P 2012-06-29 2012-06-29
US201361774991P 2013-03-08 2013-03-08
PCT/EP2013/060266 WO2013171334A1 (en) 2012-05-18 2013-05-17 Methanethione compounds having antiviral activity

Publications (3)

Publication Number Publication Date
BR112014028632A2 true BR112014028632A2 (pt) 2017-06-27
BR112014028632A8 BR112014028632A8 (pt) 2018-04-03
BR112014028632B1 BR112014028632B1 (pt) 2020-01-28

Family

ID=48444409

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028632A BR112014028632B1 (pt) 2012-05-18 2013-05-17 composto, composição farmacêutica, e, método para preparar um composto

Country Status (21)

Country Link
US (1) US9359310B2 (pt)
EP (1) EP2870141B1 (pt)
JP (2) JP6484168B2 (pt)
KR (1) KR102092207B1 (pt)
CN (1) CN104540810B (pt)
AU (1) AU2013261735B2 (pt)
BR (1) BR112014028632B1 (pt)
CA (1) CA2879816C (pt)
CL (1) CL2014003116A1 (pt)
DK (1) DK2870141T3 (pt)
EA (1) EA029044B1 (pt)
ES (1) ES2657942T3 (pt)
HK (1) HK1210165A1 (pt)
IL (1) IL235742A0 (pt)
IN (1) IN2014DN10658A (pt)
MX (1) MX356846B (pt)
MY (1) MY169094A (pt)
NZ (1) NZ702073A (pt)
SG (1) SG11201407703QA (pt)
WO (1) WO2013171334A1 (pt)
ZA (1) ZA201409220B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171334A1 (en) * 2012-05-18 2013-11-21 Vironova Ab Methanethione compounds having antiviral activity
CN107056762B (zh) * 2016-12-22 2020-08-28 四川百利药业有限责任公司 一种用作抗流感病毒的双羰基类似物
WO2021204923A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Antiviral agents
WO2021204924A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Compounds for use in the treatment of hypercytokinemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642390B2 (en) 2001-07-11 2003-11-04 Lexicon Pharmaceuticals, Inc. One step synthesis of 1,2,3-triazole carboxylic acids
EP1590329A1 (fr) * 2003-01-28 2005-11-02 Aventis Pharma S.A. Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
MX2012001504A (es) * 2009-08-05 2012-06-01 Versitech Ltd Compuestos antivirales y metodos para elaborarlos y usarlos.
CN103209977A (zh) * 2010-09-28 2013-07-17 百时美施贵宝公司 作为广谱抗流感病毒剂的带有取代的杂芳基的新的哌嗪类似物
EP2484655A1 (en) 2011-02-04 2012-08-08 Vironova AB A thionation process and a thionating agent
WO2013171334A1 (en) * 2012-05-18 2013-11-21 Vironova Ab Methanethione compounds having antiviral activity
JP6762767B2 (ja) * 2016-06-01 2020-09-30 キヤノン株式会社 撮像素子、撮像装置、および撮像信号処理方法

Also Published As

Publication number Publication date
KR20150012289A (ko) 2015-02-03
EP2870141B1 (en) 2017-11-22
NZ702073A (en) 2017-07-28
EA201401277A1 (ru) 2015-04-30
CA2879816A1 (en) 2013-11-21
MX2014014007A (es) 2015-05-11
ZA201409220B (en) 2016-08-31
US9359310B2 (en) 2016-06-07
AU2013261735A1 (en) 2015-01-22
EA029044B1 (ru) 2018-02-28
US20150133468A1 (en) 2015-05-14
EP2870141A1 (en) 2015-05-13
SG11201407703QA (en) 2015-01-29
JP2015517516A (ja) 2015-06-22
IL235742A0 (en) 2015-02-01
DK2870141T3 (da) 2018-01-29
JP2018065817A (ja) 2018-04-26
CL2014003116A1 (es) 2015-08-07
CN104540810B (zh) 2017-01-18
BR112014028632B1 (pt) 2020-01-28
MX356846B (es) 2018-06-18
CA2879816C (en) 2020-07-07
WO2013171334A1 (en) 2013-11-21
KR102092207B1 (ko) 2020-03-23
JP6484168B2 (ja) 2019-03-13
ES2657942T3 (es) 2018-03-07
IN2014DN10658A (pt) 2015-08-28
AU2013261735B2 (en) 2017-07-20
HK1210165A1 (en) 2016-04-15
BR112014028632A8 (pt) 2018-04-03
MY169094A (en) 2019-02-18
CN104540810A (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
IL251327B (en) Antiviral compounds, preparations containing them and their use for the treatment of Arnavirus infections
HK1203944A1 (zh) 用於治療和預防乙型肝炎病毒感染的 -甲基-二氫嘧啶類
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
BR112014010545A2 (pt) composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição
HK1212905A1 (zh) 用於防止登革熱病毒感染的疫苗組合物
BR112013010738A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção viral
HK1206986A1 (en) Prophylactic/therapeutic agent for influenza virus infection
EP2931310A4 (en) COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme
BR112014003556A2 (pt) método de tratamento de vírus, e, composição farmacêutica
BR112014028632A2 (pt) composto , composição farmacêutica , e , métodos de prepara um composto e de tratamento de uma infecção viral
HK1213816A1 (zh) 治療 型肝炎病毒感染的醫藥組合物
KR101501876B9 (ko) 자일리톨을 유효성분으로 함유하는 인플루엔자 바이러스 감염증 예방 또는 치료용 조성물
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus
CO6801768A2 (es) Procesos para la preparación de inhibidores del virus de la hepatitis
DK2939665T3 (da) Farmaceutisk sammensætning til behandling af hiv-infektioner
EP2931040A4 (en) METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS
HK1205680A1 (en) Agent for the treatment of hepatitis c virus
ZA201306878B (en) Treatment of hepatitis c virus infection with alisporivir
HK1209647A1 (en) Dengue virus vaccine composition
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses
HK1141664A2 (en) Composition for the treatment of infection with human influenza viruses
AU2013369626A1 (en) Dengue virus vaccine composition

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: VIRONOVA INFLUENZA AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.